Corporate Satellite Symposia and Education Theater Schedule
Schedule is subject to change. Times are listed in Pacific Time (PDT).
Wednesday, April 3
11:30 AM – 12:30 PM
Precision & Progress Against NF1: Solutions for Better Outcomes With MEKi & Multimodal Care for NF1 PNs and Other Tumors
CME Satellite Lunch Symposium (Oncology Topic)
Neurofibromatosis type 1 (NF1) is a debilitating monogenic disorder characterized by tumor growth along the nerves—with plexiform neurofibromas (PN) and optic pathway gliomas (OPG) being among the most common tumors—resulting in significant clinical medical challenges for patients, their families/caregivers, and clinicians. While conventional treatment was largely focused on surgery, chemotherapy, and radiation, the validation of targeted therapy with MEK inhibitors represents progress and ‘precision’ in modern care for patients with NF1 tumors.
Learn how to be more ‘precise’ with MEKi options by joining PeerView’s expert panel for a CME/MOC-certified Live ‘Seminars & Workshop’ event hosted at the ASPHO 2024. This workshop-style event will emphasize the importance of early tumor management, review the long-term evidence, and provide guidance on addressing practical considerations with MEKi including dosing and safety. Don’t miss this chance to learn how progress in NF1-related tumor management will affect your practice!
Learning Objectives:
- Summarize the latest clinical evidence and guideline recommendations supporting the use of MEKi for the management of NF1-associated tumors in pediatric settings, including PN, OPG, and MPNST
- Implement evidence-based management using MEKi for NF1-associated tumors based on prognostic information, patient preferences, and safety considerations
- Address practical aspects of care associated with the use of MEKi in NF1 related tumors, including patient/caregiver education, on-treatment monitoring and adverse event management
Speakers:
- Aimee Sato, MD; Seattle Children’s, UW Medicine, Seattle, Washington
- Carlos G. Romo, MD; Johns Hopkins University School of Medicine, Baltimore, Maryland
This CME/MOC activity is provided by PVI, PeerView Institute for Medical Education. This activity is supported by an educational grant from Alexion Pharmaceuticals.
11:30 AM – 12:30 PM
Mastering Asparaginase Regimens in the Care of Pediatric and AYA Patients With Acute Lymphoblastic Leukemia
CME Satellite Lunch Symposium (Hematology Topic)
Asparaginase is an integral part of pediatric ALL regimens for children and AYA patient populations. Suboptimal use of asparaginase therapy is a critical barrier to optimal outcomes and survival of patients with ALL. This program provides up-to-date information on strategies for integrating asparaginase-containing regimens for management of ALL.
Learning Objectives:
- Delineate optimal methods of identifying, measuring, and monitoring AEs associated with asparaginase therapies, including subclinical hypersensitivity and silent inactivation, in the pediatric and adolescents and young adult population undergoing treatment for ALL
- Determine instances when introducing alternative formulations of asparaginase is appropriate, in alignment with established best practices for both reexposure to asparaginase preparations and use of recombinant asparaginase
- Modify asparaginase-based treatment regimens using evidence-based agents and approaches to address hypersensitivity reactions and increase completion rates of asparaginase treatment in patients with ALL
- Evaluate current clinical evidence and expert recommendations for implementing pediatric-inspired therapeutic regimens for ALL into treatment plans for adolescents and young adults
Speakers:
- Emily Curran, MD; Assistant Professor, Department of Internal Medicine, Division of Hematology and Oncology, University of Cincinnati Cancer Center, Cincinnati, Ohio
- Stephen P. Hunger, MD; Chief, Division of Pediatric Oncology, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania
This CME symposium is sponsored by Clinical Care Options, LLC.
Thursday, April 4
12:15 – 1:30 PM
ALL IN: Staying the Course with ALL Using Therapeutic Drug Monitoring
Non-CME Satellite Lunch Symposium (Hematology Topic)
This presentation will review Asparaginase, which is foundational in the treatment of ALL, but is not without treatment challenges. We will discuss how therapeutic drug monitoring can help mitigate asparaginase treatment challenges and improve treatment outcomes for patients. And lastly discuss premedication and slowing infusion rates as options to decrease the rate of allergic reactions.
Learning Objectives:
- Describe the importance of asparaginase-based regimens in the treatment of ALL.
- Explore a clinical role for therapeutic drug monitoring in ALL treatment.
- Distinguish between clinical hypersensitivity and infusion reactions.
- Discuss options to manage and potentially mitigate asparaginase clinical hypersensitivity.
Speaker:
- Anthony Perissinotti, PharmD, BCOP, Clinical Pharmacist Specialist, Clinical Team Leader, Adjunct Clinical Assistant Professor in Pharmacy, University of Michigan
This non-CME symposium is sponsored by Servier Pharmaceuticals.
6:15 – 6:45 PM
Advancing the Treatment of PIK3CA-Related Overgrowth Spectrum Disorders with VIJOICE
Education Theater
This presentation will focus on VIJOICE, the first and only FDA-approved treatment for PIK3CA-Related Overgrowth Spectrum (PROS). Uncover insights on the impact of PROS disorders on patients' lives.
Speaker:
- Jochen Rössler, MD, Clinical Development Medical Director – Hematology, Novartis Pharmaceuticals Corporation
This educational theater is sponsored by Novartis Pharmaceuticals Corporation
7 – 8:30 PM
Pediatric Low Grade Glioma (pLGG): Disease Overview & Evolving Paradigm
Non-CME Satellite Dinner Symposium (Oncology Topic)
Learning Objectives:
- Educate physicians on various types of BRAF alterations and the need for early comprehensive testing for pLGG patients
- Communicate role of currently available BRAF inhibitors targeting MAPK pathways
- Discuss current unmet needs in pLGG treatment and the impact of treatment burden on patients
Speaker:
- Mohamed S. Abdelbaki, MD; Associate Professor of Pediatrics, Hematology and Oncology; Director, Neuro Oncology Program; Director, Neuro-Oncology Fellowship, Washington University School of Medicine in St. Louis.
This non-CME symposium is sponsored by Day One Biopharmaceuticals.
Friday, April 5
6:30 – 7:45 AM
Plasminogen Deficiency Type 1 (PLGD-1): A Pediatric Rare Disease
Non-CME Satellite Breakfast Symposium (Oncology Topic)
PLGD-1 is an ultra-rare genetic disorder characterized by the growth of fibrin-rich lesions on mucous membranes throughout the body. While both children and adults with plasminogen deficiency suffer a myriad of complications, those complications are more common, more likely to be serious, life-threatening or even fatal in childhood.
Speaker:
- Charles Nakar, MD Indiana Hemophilia & Thrombosis Center
This non-CME symposium is sponsored by Kedrion Biopharma Inc.
9:30 – 10 AM
Cellular and genetic therapies for hemoglobinopathies- a transplanter’s perspective
Education Theater
This presentation will provide an overview of allogeneic and autologous hematopoietic stem cell transplant, including gene therapy, for hemoglobinopathies.
Speaker:
- Michael Eckrich, MD, MPH; Medical Director Pediatric Transplant and Cellular Therapy, Levine Children’s Hospital, Clinical Associate Professor of Pediatrics, Wake Forest School of Medicine
This educational theater is sponsored by Vertex Pharmaceuticals.
12:45 – 1:15 PM
A look beyond chronic neutropenia- diagnosis of WHIM syndrome
Education Theater
Please join us for an engaging educational symposium focused on the signs and symptoms of WHIM (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis) syndrome, a rare, combined primary immunodeficiency associated with chronic neutropenia. Understand the challenges in the diagnostic process with the goal of improving accuracy and reducing the time to diagnosis.
Speaker:
- Shanmuganathan Chandrakasan, MD, Associate Professor; Director, Immune Dysregulation/Immunohematology and Immune Defects Transplant Programs, Aflac Cancer and Blood Disorders Center
This educational theater is sponsored by X4 Pharmaceuticals.
1:30 – 2:00 PM
Treating NF1 Plexiform Neurofibromas: Case Studies
Education Theater
Alexion invites you to join a dynamic physician-led case-based discussion with a specialist in neurofibromatosis type 1 (NF1). Zsila Sadighi, MD, a nationally recognized specialist in NF1, will discuss NF1 PN patient diagnosis, treatment, and the importance of timely intervention to optimize outcomes for patients. The presentation includes cases of pediatric NF1 patients with symptomatic, inoperable plexiform neurofibromas (PN).
Speaker:
- Zsila Sadighi, MD, Pediatric Neuro-Oncologist, Neurologist, Chief Medical Officer, Adjuvant Health
This educational theater is sponsored by Alexion Pharmaceuticals, Inc.